# HLP003 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/hlp003

> HLP003, sponsored by Helus Pharma Inc. (HELP): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | HLP003 |
| Codes | HLP003 |
| Sponsor | Helus Pharma Inc. (HELP) https://sec-api.dev/companies/help/catalysts |
| Indications | [moderate to severe mdd](https://sec-api.dev/indications/moderate-to-severe-mdd) |
| Modality |  |
| FDA designations | breakthrough |

## Timeline

### October 31, 2023: interim data readout

- Status: completed, met. Date confidence: exact. Stage: 2. Indication: moderate to severe MDD.
- First seen 2026-02-13, last confirmed 2026-08-14.
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000058): "On October 31, 2023, the Company announced Phase 2a interim results for HLP003, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12 mg dose compared to placebo, in participants with moderate to severe MDD." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000058/cybin-mdaxq1x27.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000012): "On October 31, 2023, the Company announced Phase 2a interim results for HLP003, demonstrating a rapid, robust and statistically significant reduction in symptoms of depression three weeks following a single 12 mg dose compared to placebo, in participants with moderate to severe MDD." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000012/cybin-mdaxq3x26.htm

### November 30, 2023: topline data readout

- Status: completed, met. Date confidence: exact. Stage: 2.
- First seen 2026-02-13, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000100): "On November 30, 2023, the Company announced positive Phase 2a topline results for HLP003, showing rapid and robust improvements in symptoms of depression after single doses of HLP003, with an average 14.1 point difference in MADRS score reduction between HLP003 and placebo which was statistically significant at 3 weeks (p<0.0001)." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000058): "On November 30, 2023, the Company announced positive Phase 2a topline results for HLP003, showing rapid and robust improvements in symptoms of depression after single doses of HLP003, with an average 14.1 point difference in MADRS score reduction between HLP003 and placebo which was statistically significant at 3 weeks (p<0.0001)." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000058/cybin-mdaxq1x27.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000012): "On November 30, 2023, the Company announced positive Phase 2a topline results for HLP003, showing rapid and robust improvements in symptoms of depression after single doses of HLP003, with an average 14.1 point difference in MADRS score reduction between HLP003 and placebo which was statistically significant at 3 weeks (p<0.0001)." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000012/cybin-mdaxq3x26.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-02-13, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000094): "The Company continues to anticipate reporting topline data from its Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder in Q4 2026." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000094/materialchangereport-leade.htm
- Press release filed with the SEC (EX-99) (accession 0001062993-26-005562): "The Company continues to anticipate reporting topline data from its Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder in Q4 2026." https://www.sec.gov/Archives/edgar/data/1833141/000106299326005562/exhibit99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001062993-26-003976): "Appointed as Helus Pharma prepares for topline data readout from APPROACH, the first pivotal Phase 3 Study of HLP003 as an adjunctive treatment for Major Depressive Disorder ("MDD"), expected in Q4 2026" https://www.sec.gov/Archives/edgar/data/1833141/000106299326003976/exhibit99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000012): "•Continued execution of the APPROACH™ pivotal Phase 3 study evaluating HLP003 as an adjunctive treatment for MDD with topline data anticipated in Q4 2026." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000012/q3earningspr2026.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000050): ""With participant enrollment now complete, our focus turns to completing the study and preparing for topline data in Q4 2026.1,2 We believe the durability, remission rates, and overall profile demonstrated in our Phase 2 study support the potential of HLP003 to meaningfully improve outcomes for patients living with MDD, and we look forward to advancing the program through the next stage of development and toward a potential FDA New Drug Application in 2028."1,2" https://www.sec.gov/Archives/edgar/data/1833141/000183314126000050/final2026-07x21approachenr.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000100): "The Company's near-term prospects and the market price of the Common Shares depend substantially on the success of HLP003, including the topline results of APPROACH expected in Q4 2026, the completion of EMBRACE and EXTEND, and the submission and acceptance of an NDA, regulatory approval and DEA rescheduling." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm
- Press release filed with the SEC (EX-99) (accession 0001062993-26-003976): "Forward-looking statements in this news release include statements regarding the Company's plan to readout HLP003 topline data in the fourth quarter of 2026; the Company's expectation that HLP003 will be a differentiated new option in the adjunctive landscape for patients living with MDD; the potential of HLP003 to transform the treatment paradigm for MDD; the potential of HLP003 to meaningfully improve outcomes for patients living with MDD; the commercialization of HLP003; the Company's continued growth; and plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions." https://www.sec.gov/Archives/edgar/data/1833141/000106299326003976/exhibit99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001062993-26-003338): "Forward-looking statements in this news release include statements regarding the Company's plan to readout topline data in the fourth quarter of 2026; the Company's expectation that HLP003 is a transformative treatment option for patients living with MDD; the Company's progress on and expectations with respect to the APPROACH trial; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions." https://www.sec.gov/Archives/edgar/data/1833141/000106299326003338/exhibit99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001062993-26-003338): "- Company remains on track for topline data readout in Q4 2026 -" https://www.sec.gov/Archives/edgar/data/1833141/000106299326003338/exhibit99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000050): "Completion of enrollment represents an important milestone for Helus Pharma and advances the Company toward the expected release of topline data in the fourth quarter of 2026.1,2" https://www.sec.gov/Archives/edgar/data/1833141/000183314126000050/final2026-07x21approachenr.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000050): "•Topline data release to include both the primary and key secondary endpoints and is on track for Q4 2026.1,2" https://www.sec.gov/Archives/edgar/data/1833141/000183314126000050/final2026-07x21approachenr.htm
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000050): "Forward-looking statements in this news release include statements regarding the Company's plan to readout topline data in the fourth quarter of 2026" https://www.sec.gov/Archives/edgar/data/1833141/000183314126000050/final2026-07x21approachenr.htm

### Q4 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-11-13, last confirmed 2026-11-13.
- Press release filed with the SEC (EX-99) (accession 0001833141-26-000100): "The Company's near-term prospects and the market price of the Common Shares depend substantially on the success of HLP003, including the topline results of APPROACH expected in Q4 2026, the completion of EMBRACE and EXTEND, and the submission and acceptance of an NDA, regulatory approval and DEA rescheduling." https://www.sec.gov/Archives/edgar/data/1833141/000183314126000100/helus-mdaxq2x27.htm

## Same indication

- [CYB003](https://sec-api.dev/pdufa/cyb003) (HELP)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/hlp003.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HLP003 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/hlp003

```bibtex
@misc{secapidev_pdufa_hlp003_20261116,
  title        = {HLP003 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/hlp003}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_hlp003_20261116","title":"HLP003 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/hlp003","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
